Here, we attempted to identify targets that could be used to overcome resistance toward epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.